Back to today’s briefing

Story perspectives

Genetic Mutation Weakens Tumor Defense, Sparks New Therapy Hope

7/3/2025

46 7

Summary

Story summary

A groundbreaking study from UC Davis uncovers a genetic mutation in humans that weakens the immune protein Fas Ligand's ability to combat solid tumors, a stark contrast to primates. This mutation, associated with our larger brains, gives tumors an edge. However, targeting the enzyme plasmin could boost cancer immunotherapy, paving the way for innovative treatment options.

1 of 1

Story summary

A groundbreaking study from UC Davis uncovers a genetic mutation in humans that weakens the immune protein Fas Ligand's ability to combat solid tumors, a stark contrast to primates. This mutation, associated with our larger brains, gives tumors an edge. However, targeting the enzyme plasmin could boost cancer immunotherapy, paving the way for innovative treatment options.